C2 Biotechnologies’ goals are to produce and sell consumables that facilitate and reduce costs of fermentation processes. Long term diversification goals include production of other biologics for diagnostics and treatment of specific disease conditions.
C2 Biotechnologies is a Limited Liability Company (LLC) founded in 2006 and located in Ulster County, New York. The company will use advanced molecular biology technology to produce industrial enzymes for use in chemical reactions.
The products we produce are necessary for the conversion of complex carbohydrates to simple sugars that are then converted by organisms to ethanol used in bio-fuels. Yeasts and/or bacteria can feed on simple carbon sources (sugar) and result in the production of ethanol as a waste product. Carbon sources like corn or wood contain complex carbohydrates that yeast can not metabolize. Enzymes can be used to convert these complex carbon sources to simple sugars. Physical processes of mechanically breaking and heating can reduce complex carbohydrates to simple sugars but this is slow, expensive, and inefficient and also can be hazardous.
The use of our recombinant enzymes thus increases efficiency and yield leading to significant reduction in costs. The technology used to produce recombinant enzymes are environmentally safe.
 |
|
- C2 Biotechnologies Principal
- Larry Cosenza, Ph.D., Founder & Chief Science Manager
- Extensive background in protein engineering, molecular, structural and computational biology
- Has national and international research experience
- Ph.D. Pharmacology, Boston University, 1998.
- M.A. Biochemistry, Boston University, 1992
- Research interests involve understanding the
relationship between structure and biological activity. - Contact: (205) 586 - 9163
|
